patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_444564 | REC_0008901 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.5 | 76 | female | 2 | 24 | 6.3 | 6 | entrectinib 600 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:59.047497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400649 | REC_0008902 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12 | 69 | male | 1 | 11 | 5.3 | 1 | entrectinib 600 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:59.047756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711159 | REC_0008903 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 11 | 60 | female | 1 | 19 | 6.8 | 6 | pembrolizumab 200 mg q3w | 11.9 | true | MSI-H | 2026-03-15T05:35:59.048013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802877 | REC_0008904 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.7 | 65 | male | 1 | 68 | 5.3 | 6 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:35:59.048324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387363 | REC_0008905 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 17.3 | 71 | female | 1 | 11 | 5.2 | 7 | osimertinib 80 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:59.048581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286098 | REC_0008906 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 6.2 | 65 | female | 0 | 15 | 5.9 | 8 | sotorasib 960 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.048940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414772 | REC_0008907 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.3 | 65 | male | 0 | 19 | 6.8 | 6 | osimertinib 80 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:59.049264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912994 | REC_0008908 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 4.5 | 77 | female | 3 | 78 | 5.1 | 1 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:59.049516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534071 | REC_0008909 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.6 | 74 | female | 3 | 19 | 4.3 | 7 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:59.049758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851430 | REC_0008910 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 8.7 | 73 | female | 2 | 15 | 4.5 | 2 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.049994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961050 | REC_0008911 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.2 | 68 | female | 1 | 17 | 6.4 | 3 | osimertinib 80 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:59.050229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136407 | REC_0008912 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.2 | 68 | female | 1 | 21 | 4.3 | 2 | pembrolizumab 200 mg q3w | 20.1 | true | MSS | 2026-03-15T05:35:59.050462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700919 | REC_0008913 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 8.8 | 55 | female | 0 | 13 | 5.2 | 5 | sotorasib 960 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:59.050701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804040 | REC_0008914 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.1 | 71 | female | 2 | 18 | 5.1 | 3 | sotorasib 960 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:59.051006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948823 | REC_0008915 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 4 | 63 | male | 1 | 61 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.051250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784105 | REC_0008916 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 14.9 | 70 | female | 2 | 16 | 8 | 1 | osimertinib 80 mg daily | 18.4 | true | MSS | 2026-03-15T05:35:59.051489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137638 | REC_0008917 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 10.8 | 50 | male | 0 | 24 | 4.2 | 2 | osimertinib 80 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:35:59.051733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763713 | REC_0008918 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 7.6 | 66 | female | 1 | 10 | 3.4 | 10 | alectinib 600 mg BID | 12.9 | false | MSS | 2026-03-15T05:35:59.051978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594703 | REC_0008919 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 9.6 | 73 | female | 1 | 85 | 7.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.7 | true | MSS | 2026-03-15T05:35:59.052423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550086 | REC_0008920 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.9 | 47 | female | 0 | 20 | 7 | 5 | sotorasib 960 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:59.052688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382666 | REC_0008921 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.6 | 55 | male | 0 | 8 | 3.7 | 7 | entrectinib 600 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:59.052941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799711 | REC_0008922 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 9.9 | 73 | female | 2 | 25 | 5.4 | 0 | sotorasib 960 mg daily | 43.1 | true | MSS | 2026-03-15T05:35:59.053181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315941 | REC_0008923 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 10 | 60 | female | 0 | 7 | 7.3 | 0 | osimertinib 80 mg daily | 45.2 | true | MSI-H | 2026-03-15T05:35:59.053426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522624 | REC_0008924 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 11.7 | 51 | male | 0 | 13 | 5.5 | 1 | osimertinib 80 mg daily | 29.6 | true | MSI-H | 2026-03-15T05:35:59.053676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983545 | REC_0008925 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 18.1 | 57 | female | 0 | 18 | 5.7 | 9 | alectinib 600 mg BID | 5.2 | false | MSS | 2026-03-15T05:35:59.053924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741276 | REC_0008926 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.9 | 79 | male | 1 | 8 | 3 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.054166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841112 | REC_0008927 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.8 | 74 | female | 1 | 9 | 5.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:35:59.054409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785763 | REC_0008928 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 15.6 | 52 | female | 0 | 11 | 5.9 | 0 | osimertinib 80 mg daily | 53.8 | true | MSS | 2026-03-15T05:35:59.054657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_642388 | REC_0008929 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.3 | 61 | female | 0 | 12 | 3.2 | 6 | alectinib 600 mg BID | 7.6 | true | MSI-H | 2026-03-15T05:35:59.054902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164929 | REC_0008930 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.2 | 69 | male | 0 | 8 | 5.8 | 2 | sotorasib 960 mg daily | 17.6 | false | MSS | 2026-03-15T05:35:59.055138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373840 | REC_0008931 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.2 | 62 | male | 0 | 24 | 3.4 | 5 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:59.055375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383187 | REC_0008932 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 11.4 | 64 | female | 1 | 31 | 5.6 | 6 | alectinib 600 mg BID | 20 | false | MSS | 2026-03-15T05:35:59.055713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845214 | REC_0008933 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 13 | 18.6 | 77 | male | 2 | 19 | 5.7 | 6 | osimertinib 80 mg daily | 9 | false | MSS | 2026-03-15T05:35:59.055960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101877 | REC_0008934 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 30 | 13.2 | 70 | female | 2 | 19 | 4 | 0 | alectinib 600 mg BID | 60.7 | true | MSI-H | 2026-03-15T05:35:59.056505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508807 | REC_0008935 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 6.8 | 57 | male | 0 | 9 | 2.5 | 5 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:59.057060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997791 | REC_0008936 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 9.4 | 76 | female | 2 | 17 | 5.9 | 1 | sotorasib 960 mg daily | 29.1 | false | MSS | 2026-03-15T05:35:59.057498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978284 | REC_0008937 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 13.2 | 73 | female | 1 | 15 | 6 | 2 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:59.057921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721615 | REC_0008938 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 7.7 | 76 | female | 0 | 1 | 5.6 | 4 | alectinib 600 mg BID | 14.3 | false | MSS | 2026-03-15T05:35:59.058304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587364 | REC_0008939 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 14.8 | 62 | female | 0 | 8 | 5 | 7 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:59.058549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687933 | REC_0008940 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 13.3 | 69 | female | 0 | 23 | 6.3 | 2 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:59.058787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336168 | REC_0008941 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.3 | 82 | female | 1 | 40 | 6.4 | 1 | pembrolizumab 200 mg q3w | 11.2 | true | MSS | 2026-03-15T05:35:59.059026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707214 | REC_0008942 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.2 | 60 | female | 1 | 3 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:35:59.059267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943436 | REC_0008943 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 17.8 | 65 | male | 1 | 11 | 4.5 | 7 | osimertinib 80 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:35:59.059506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478544 | REC_0008944 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.5 | 68 | female | 1 | 46 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:59.059734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682507 | REC_0008945 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 12 | 12 | 63 | male | 1 | 24 | 5.6 | 2 | osimertinib 80 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:35:59.060106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116787 | REC_0008946 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 13.5 | 78 | male | 1 | 22 | 6 | 1 | sotorasib 960 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:59.060372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873317 | REC_0008947 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.8 | 72 | female | 2 | 33 | 4.3 | 5 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:59.060616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735436 | REC_0008948 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 21 | 10.8 | 65 | male | 0 | 7 | 5.1 | 0 | pembrolizumab 200 mg q3w | 44.2 | true | MSS | 2026-03-15T05:35:59.060861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791444 | REC_0008949 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.9 | 55 | female | 1 | 17 | 4.7 | 8 | entrectinib 600 mg daily | 6 | true | MSI-H | 2026-03-15T05:35:59.061115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553390 | REC_0008950 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.7 | 66 | female | 0 | 15 | 4.8 | 0 | alectinib 600 mg BID | 21.4 | true | MSS | 2026-03-15T05:35:59.061367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506466 | REC_0008951 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 17.4 | 54 | male | 0 | 10 | 7.2 | 9 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:59.061610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480544 | REC_0008952 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.9 | 76 | female | 3 | 20 | 4.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.2 | true | MSS | 2026-03-15T05:35:59.061842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737626 | REC_0008953 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.5 | 80 | female | 1 | 6 | 5.9 | 6 | alectinib 600 mg BID | 12.2 | true | MSI-H | 2026-03-15T05:35:59.062091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911918 | REC_0008954 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.4 | 66 | female | 1 | 49 | 4.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.1 | false | MSS | 2026-03-15T05:35:59.062334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780326 | REC_0008955 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.7 | 64 | female | 1 | 6 | 6.8 | 1 | alectinib 600 mg BID | 20.4 | true | MSS | 2026-03-15T05:35:59.062589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176013 | REC_0008956 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.8 | 59 | male | 1 | 21 | 5.4 | 2 | osimertinib 80 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:59.062844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367137 | REC_0008957 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 12.4 | 62 | male | 1 | 12 | 4.5 | 1 | pembrolizumab 200 mg q3w | 8.4 | false | MSI-H | 2026-03-15T05:35:59.063098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149607 | REC_0008958 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.7 | 74 | female | 1 | 19 | 6.2 | 5 | sotorasib 960 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:59.063504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537872 | REC_0008959 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.2 | 68 | female | 0 | 11 | 5 | 6 | pembrolizumab 200 mg q3w | 5.1 | false | MSS | 2026-03-15T05:35:59.063780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103210 | REC_0008960 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 18.5 | 74 | male | 2 | 11 | 6.8 | 1 | entrectinib 600 mg daily | 16.7 | true | MSS | 2026-03-15T05:35:59.064040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152665 | REC_0008961 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16.2 | 65 | male | 0 | 23 | 5.5 | 5 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:35:59.064436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173412 | REC_0008962 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.1 | 73 | female | 2 | 21 | 7.8 | 5 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:35:59.064710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577629 | REC_0008963 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 16.2 | 51 | female | 0 | 20 | 7.1 | 7 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:59.064973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864208 | REC_0008964 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 7.1 | 66 | female | 0 | 54 | 5.7 | 2 | pembrolizumab 200 mg q3w | 24.3 | true | MSS | 2026-03-15T05:35:59.065221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994533 | REC_0008965 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 7.4 | 70 | female | 2 | 35 | 4.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.1 | true | MSS | 2026-03-15T05:35:59.065470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536870 | REC_0008966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.1 | 69 | male | 0 | 7 | 4.9 | 7 | entrectinib 600 mg daily | 6.4 | true | MSS | 2026-03-15T05:35:59.065717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837184 | REC_0008967 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 10 | 68 | female | 0 | 26 | 3.7 | 7 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:59.065965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676365 | REC_0008968 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 7.4 | 59 | female | 1 | 23 | 3.9 | 6 | sotorasib 960 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:59.066201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750617 | REC_0008969 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6.9 | 61 | male | 0 | 48 | 7.6 | 9 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:59.066439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427226 | REC_0008970 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9.9 | 52 | female | 0 | 18 | 5.2 | 1 | sotorasib 960 mg daily | 21.7 | false | MSS | 2026-03-15T05:35:59.066675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223896 | REC_0008971 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 4.3 | 70 | female | 1 | 22 | 5 | 3 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:35:59.067025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969197 | REC_0008972 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 7.6 | 64 | male | 1 | 22 | 6.8 | 2 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:35:59.067268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253727 | REC_0008973 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 12.9 | 60 | female | 1 | 17 | 5.7 | 6 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:59.067508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456595 | REC_0008974 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 6.4 | 64 | female | 1 | 10 | 4.6 | 4 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:59.067750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223419 | REC_0008975 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 9.6 | 80 | male | 1 | 15 | 4 | 0 | entrectinib 600 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:59.067988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465419 | REC_0008976 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 6.2 | 80 | female | 2 | 21 | 4.7 | 1 | pembrolizumab 200 mg q3w | 22.2 | true | MSS | 2026-03-15T05:35:59.068300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353459 | REC_0008977 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 13.2 | 67 | female | 1 | 10 | 6.5 | 3 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:35:59.068558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759492 | REC_0008978 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 20.4 | 70 | female | 2 | 12 | 8.1 | 8 | alectinib 600 mg BID | 19.1 | false | MSS | 2026-03-15T05:35:59.068801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516464 | REC_0008979 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.7 | 78 | female | 1 | 10 | 6.7 | 2 | sotorasib 960 mg daily | 21.7 | false | MSI-H | 2026-03-15T05:35:59.069042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566195 | REC_0008980 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 36 | 5 | 64 | male | 1 | 30 | 7.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.5 | true | MSS | 2026-03-15T05:35:59.069279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944336 | REC_0008981 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 8.3 | 57 | male | 1 | 11 | 4.9 | 1 | sotorasib 960 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:59.069513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811603 | REC_0008982 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 10.2 | 59 | male | 1 | 8 | 6.8 | 2 | osimertinib 80 mg daily | 29.3 | true | MSS | 2026-03-15T05:35:59.069751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518209 | REC_0008983 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 8.6 | 64 | male | 1 | 40 | 4.7 | 1 | pembrolizumab 200 mg q3w | 20.1 | false | MSS | 2026-03-15T05:35:59.069991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995192 | REC_0008984 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 9.1 | 66 | male | 0 | 3 | 5.5 | 4 | entrectinib 600 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.070342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719169 | REC_0008985 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.4 | 60 | male | 0 | 26 | 3.9 | 7 | alectinib 600 mg BID | 7.1 | true | MSI-H | 2026-03-15T05:35:59.070608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953993 | REC_0008986 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 13.1 | 72 | female | 1 | 14 | 6.4 | 0 | osimertinib 80 mg daily | 30 | true | MSI-H | 2026-03-15T05:35:59.070860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107247 | REC_0008987 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 17.5 | 64 | male | 1 | 14 | 5.9 | 6 | osimertinib 80 mg daily | 6.5 | true | MSI-H | 2026-03-15T05:35:59.071122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301597 | REC_0008988 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.3 | 56 | female | 1 | 40 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.9 | false | MSS | 2026-03-15T05:35:59.071372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111691 | REC_0008989 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.1 | 68 | female | 0 | 3 | 2.2 | 6 | sotorasib 960 mg daily | 6 | true | MSS | 2026-03-15T05:35:59.071622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177830 | REC_0008990 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 18 | 65 | male | 1 | 19 | 7 | 5 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:59.071878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577680 | REC_0008991 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.2 | 70 | female | 1 | 33 | 4.7 | 6 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:59.072177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296566 | REC_0008992 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5.5 | 72 | female | 1 | 63 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.4 | true | MSS | 2026-03-15T05:35:59.072444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736691 | REC_0008993 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 3.6 | 84 | female | 2 | 59 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.7 | false | MSS | 2026-03-15T05:35:59.072698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391211 | REC_0008994 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 2.9 | 64 | male | 1 | 13 | 5.3 | 1 | sotorasib 960 mg daily | 21.3 | false | MSS | 2026-03-15T05:35:59.072952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655179 | REC_0008995 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 1.7 | 83 | female | 2 | 32 | 2.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.9 | true | MSS | 2026-03-15T05:35:59.073205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747186 | REC_0008996 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9.4 | 72 | male | 1 | 44 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:59.073449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515320 | REC_0008997 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 6.8 | 67 | female | 0 | 65 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:35:59.073784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921521 | REC_0008998 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 15.9 | 64 | female | 0 | 17 | 6.6 | 5 | entrectinib 600 mg daily | 8.5 | true | MSS | 2026-03-15T05:35:59.074037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848190 | REC_0008999 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.5 | 53 | female | 0 | 67 | 7.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.3 | false | MSS | 2026-03-15T05:35:59.074285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475774 | REC_0009000 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 11 | 74 | female | 1 | 15 | 4.5 | 5 | osimertinib 80 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:35:59.074532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.